1.Department of Nephrology, the Second Hospital of Shanxi Medical University, Shanxi Province, Taiyuan 030000, China;
2.Department of Nephrology, Shenzhen Baoan Shiyan People′s Hospital, Guangdong Province, Shenzhen 518005, China
Abstract：Diabetic nephropathy (DN) is one of the main complications of diabetic microangiopathy and has been the leading cause of chronic kidney disease in China. It′s important to understand the pathogenesis and find new diagnostic and therapeutic targets of DN. MicroRNA (miRNA), as a ubiquitous non-coding small molecular RNA, is widely involved in gene post-transcriptional and epigenetic regulations. The expression or abnormal function play an important role in the occurrence and development of DN, mediating the pathophysiological changes such as the pathophysiological changes of renal tissue fibrosis, inflammation, podocyte apoptosis in DN. Recently, the value of miRNA in the early diagnosis and prognosis judgment of DN has been confirmed and it has been gradually used in clinical treatment as a therapeutic target for DN by inhibiting or reconstructing miRNA. However, there are great challenges of miRNA in the pathogenesis and clinical application for DN in the future.
[1] Cho NH，Shaw JE，Karuranga S，et al. IDF Diabetes Atlas：Global estimates of diabetes prevalence for 2017 and projections for 2045 [J]. Diabetes Res Clin Pract，2018，138：271-281.
[2] Zhang L，Long J，Jiang W，et al. Trends in Chronic Kidney Disease in China [J]. N Engl J Med，2016，375（9）：905-906.
[3] Badal SS，Danesh FR. New insights into molecular mechanisms of diabetic kidney disease [J]. Am J Kidney Dis，2014， 63（2 Suppl 2）：S63-S83.
[4] Shikata K，Makino H. Microinflammation in the Pathogenesis of Diabetic Nephropathy [J]. J Diabetes Investig，2013， 4（2）：142-149.
[5] Dewanjee S，Bhattach N. MicroRNA：A new generation therapeutic target in diabetic nephropathy [J]. Biochem Pharmacol，2018，155：32-47.
[6] Palazzo AF，Lee ES. Non-coding RNA：what is functional and what is junk? [J]. Front Genet，2015，6：2.
[7] Sankrit H，Kulk YA，Gaikwad AB. Diabetic nephropathy：The regulatory interplay between epigenetics and microRNAs [J]. Pharmacol Res，2019，141：574-585.
[8] Assmann TS，Recamonde-Mendoza M，de Souza BM，et al. MicroRNAs and diabetic kidney disease：Systematic review and bioinformatic analysis [J]. Mol Cell Endocrinol，2018，477：90-102.
[9] Kato M，Dang V，Wang M，et al. TGF-beta induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy[J]. Sci Signal，2013，6（278）：ra43.
[10] Liu F，Zhang ZP，Xin GD，et al. miR-192 prevents renal tubulointerstitial fibrosis in diabetic nephropathy by targeting Egr1 [J]. Eur Rev Med Pharmacol Sci，2018，22（13）：4252-4260.
[11] Ma X，Lu C，Lv C，et al. The Expression of miR-192 and Its Significance in Diabetic Nephropathy Patients with Different Urine Albumin Creatinine Ratio [J]. J Diabetes Res，2016，2016：6789402.
[12] McClell AD，Herman-Edelstein M，Komers R，et al. miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7 [J]. Clin Sci（Lond），2015， 129（12）：1237-1249.
[13] Chen X，Zhao L，Xing Y，et al. Down-regulation of microRNA-21 reduces inflammation and podocyte apoptosis in diabetic nephropathy by relieving the repression of TIMP3 expression [J]. Biomed Pharmacother，2018，108：7-14.
[14] Liu L，Wang Y，Yan R，et al. BMP-7 inhibits renal fibrosis in diabetic nephropathy via miR-21 downregulation [J]. Life Sci，2019，238：116957.
[15] Baker MA，Davis SJ，Liu P，et al. Tissue-Specific MicroRNA Expression Patterns in Four Types of Kidney Disease [J]. J Am Soc Nephrol，2017，28（10）：2985-2992.
[16] Pezzolesi MG，Satake E，McDonnell KP，et al. Circulating TGF-beta1-Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes [J]. Diabetes，2015，64（9）：3285-3293.
[17] Hsu YC，Chang PJ，Ho C，et al. Protective effects of miR-29a on diabetic glomerular dysfunction by modulation of DKK1/Wnt/beta-catenin signaling [J]. Sci Rep，2016，6：30575.
[18] Bao L，Li J，Zha D，et al. Chlorogenic acid prevents diabetic nephropathy by inhibiting oxidative stress and inflammation through modulation of the Nrf2/HO-1 and NF-κB pathways [J]. Int Immunopharmacol，2018，54：245-253.
[19] Sun SF，Tang PMK，Feng M，et al. Novel lncRNA Erbb4-IR Promotes Diabetic Kidney Injury in db/db Mice by Targeting miR-29b [J]. Diabetes，2018，67（4）：731-744.
[20] Guo J，Li J，Zhao J，et al. MiRNA-29c regulates the expression of inflammatory cytokines in diabetic nephropathy by targeting tristetraprolin [J]. Sci Rep，2017，7（1）：2314.
[21] Kanasaki K，Shi S，Kanasaki M，et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen [J]. Diabetes，2014，63（6）：2120-2131.
[22] Chen HY，Zhong X，Huang XR，et al. MicroRNA-29b inhibits diabetic nephropathy in db/db mice [J]. Mol Ther，2014，22（4）：842-853.
[23] Card-Gonzalez M，Srivastava A，Pavkovic M，et al. Identification，Confirmation，and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy [J]. Clin Chem，2017，63（9）：1515-1526.
[24] Consez F，Barozzino M，Pesce F，et al. Urinary miRNA-27b-3p and miRNA-1228-3p correlate with the progression of Kidney Fibrosis in Diabetic Nephropathy [J]. Sci Rep，2019，9（1）：11357.
[25] Eissa S，Matboli M，Bek MM. Clinical verification of a novel urinary microRNA panal：133b，-342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis [J]. Biomed Pharmacother，2016，83：92-99.
[26] Roux M，Perret C，Feigerlova E. Plasma levels of hsa-miR-152-3p are associated with diabetic nephropathy in patients with type 2 diabetes [J]. Nephrol Dial Transplant，2018，33（12）：2201-2207.
[27] Barutta F，Bruno G，Matullo G. MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study [J]. Acta Diabetol，2017，54（2）：133-139.
[28] Kato M. Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease [J]. Kidney Res Clin Pract，2018，37（3）：197-209.
[29] Roos M，Pradere U，Ngondo RP，et al. A Small-Molecule Inhibitor of Lin28 [J]. ACS Chem Biol，2016，11（10）：2773-2781.
[30] Liu R，Das B，Xiao W，et al. A Novel Inhibitor of Homeodomain Interacting Protein Kinase 2 Mitigates Kidney Fibrosis through Inhibition of the TGF-beta1/Smad3 Pathway [J]. J Am Soc Nephrol，2017，28（7）：2133-2143.
2020, Vol. 17 
京公网安备 11010502046598号